Earnings In Brief
This article was originally published in The Gray Sheet
Executive Summary
CryoCath's AF results: Arctic Front cryoablation system with FlexCath deflectable sheath to treat atrial fibrillation achieved a chronic efficacy rate of over 80% at 6 months in a 20-patient U.S. trial, according to CryoCath CEO Steve Arless. The firm reported no long-term safety issues, though two patients did have to be re-treated early on. "If the data continue to build as with the first 20 patients, we'll certainly corner the vast majority of the [atrial fibrillation] market. But the interesting thing we will address longer term is what role [Arctic Front] will play in the treatment of ventricular tachycardia, where implantable defibrillators play a huge role right now," Arless said. For the quarter ended Dec. 31, the firm reported revenue of $8.9 mil., up 48% over the prior-year period...
You may also be interested in...
Mentor’s Stock Jumps In Q3 On Silicone Implant “Approvable” Letter
FDA's "approvable" letter to Mentor for the Memory Gel silicone breast implants drove the firm's stock up 32.6% to $55.01 for the quarter, but investor tunnel-vision could keep future stock movement tied to FDA's final decision
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.